AIM: To explore and detail clinical experiences of dabigatran, a novel anticoagulant, after it became available in New Zealand in July 2011. METHODS:A cohort of patients was recruited from Hutt Hospital and the two largest primary care practices in the Hutt Valley region. They were included if they took at least one dose of dabigatran between July 2011 and April 2012. Participants undertook a questionnaire 3-12 months after starting dabigatran assessing adherence, perceived side-effects and complications. Those presenting due to an adverse event were analysed separately. RESULTS: Of 102 patients identified, 92 were recruited to this study. At a median of 8 months, 70% of participants were still taking dabigatran, significantly lower than in the RE-LY trial at 12 months (P = 0.0002). The commonest reason given for discontinuation was gastrointestinal (GI) side-effects. Rates of serious adverse outcomes on dabigatran therapy were relatively low. Patients expressed polarised comments, both positive and negative, regarding their experiences of dabigatran. CONCLUSIONS: A high rate of discontinuation of dabigatran, mainly due to GI symptoms, was observed. There does not appear to be any specific predictor of dabigatran tolerance. When prescribed according to guidelines, rates of serious adverse events associated with dabigatran appear to be low.
RCT Entities:
AIM: To explore and detail clinical experiences of dabigatran, a novel anticoagulant, after it became available in New Zealand in July 2011. METHODS: A cohort of patients was recruited from Hutt Hospital and the two largest primary care practices in the Hutt Valley region. They were included if they took at least one dose of dabigatran between July 2011 and April 2012. Participants undertook a questionnaire 3-12 months after starting dabigatran assessing adherence, perceived side-effects and complications. Those presenting due to an adverse event were analysed separately. RESULTS: Of 102 patients identified, 92 were recruited to this study. At a median of 8 months, 70% of participants were still taking dabigatran, significantly lower than in the RE-LY trial at 12 months (P = 0.0002). The commonest reason given for discontinuation was gastrointestinal (GI) side-effects. Rates of serious adverse outcomes on dabigatran therapy were relatively low. Patients expressed polarised comments, both positive and negative, regarding their experiences of dabigatran. CONCLUSIONS: A high rate of discontinuation of dabigatran, mainly due to GI symptoms, was observed. There does not appear to be any specific predictor of dabigatran tolerance. When prescribed according to guidelines, rates of serious adverse events associated with dabigatran appear to be low.
Authors: Julie C Lauffenburger; Joel F Farley; Anil K Gehi; Denise H Rhoney; M Alan Brookhart; Gang Fang Journal: J Am Heart Assoc Date: 2015-04-10 Impact factor: 5.501
Authors: Brian Godman; Rickard E Malmström; Eduardo Diogene; Sisira Jayathissa; Stuart McTaggart; Thomas Cars; Samantha Alvarez-Madrazo; Christoph Baumgärtel; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Irene Eriksson; Alexander Finlayson; Jurij Fürst; Kristina Garuoliene; Iñaki Gutiérrez-Ibarluzea; Krystyna Hviding; Harald Herholz; Roberta Joppi; Marija Kalaba; Ott Laius; Kamila Malinowska; Hanne B Pedersen; Vanda Markovic-Pekovic; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Susan Spillane; Dominik Tomek; Luka Vončina; Vera Vlahović-Palčevski; Janet Wale; Magdalena Wladysiuk; Menno van Woerkom; Corinne Zara; Lars L Gustafsson Journal: Front Pharmacol Date: 2014-06-10 Impact factor: 5.810
Authors: Tanja Mueller; Samantha Alvarez-Madrazo; Chris Robertson; Marion Bennie Journal: Pharmacoepidemiol Drug Saf Date: 2017-07-28 Impact factor: 2.890